With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

This health crisis is largely attributed to sedentary lifestyles, excessive consumption of processed and fast food, and ...

“Chronic kidney disease is a global healthcare problem ... GLP-1 agonists – LEADER with liraglutide and SUSTAIN-6 with semaglutide – in which we included important renal endpoints.

Locally produced versions of drugs like Semaglutide are helpful for patients with obesity and diabetes, but unprescribed use raises concerns ...

FAT JABS have taken the nation’s waistline by storm – trimming inches and helping thousands shed weight, and fast. But it ...

Pharma giant Eli Lilly’s weight loss drug Mounjaro is priced between Rs. 10,000- ₹15,000 in India making it inaccessible to a ...

It may not be the mythical fountain of youth, but the strength of the body's immune system, or immune resilience, could hold ...

Weight loss drugs have become an increasingly popular, but controversial, way of quickly shedding extra pounds over the past ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

And GLP-1 agonists were associated with an 8% lower mortality risk as well (HR 0.92, 95% CI 0.87-0.97), according to findings ...

were 26% more likely to develop kidney disease in the first year of life than those not exposed. They also faced notably high risks for chronic, unspecified, and diabetic kidney diseases as they ...

Approximately 1 in 10 patients with lupus nephritis eventually progresses to kidney failure. Longer remission may help prevent chronic kidney disease (CKD) onset.